CIPLA SALBUTAMOL INHALER (Cipla Australia Pty Ltd)
Product name
CIPLA SALBUTAMOL INHALER
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
186 (255 working days)
Active ingredients
salbutamol sulfate
Registration type
New generic medicine
Indication
[TRADE NAME] is indicated for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.